![Ziad Mirza](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ziad Mirza
Gründer bei Baltimore Medical & Surgical Associates
Aktive Positionen von Ziad Mirza
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Baltimore Medical & Surgical Associates | Gründer | - | - |
Präsident | - | - | |
Greater Baltimore Medical Center
![]() Greater Baltimore Medical Center Hospital/Nursing ManagementHealth Services Greater Baltimore Medical Center provides health care services. It is a nearly 310 bed hospital which also operates the Hospice of Baltimore, the Hospice of Howard County, the Gilchrist Center for Hospice Care, plus various clinics and medical offices. Greater Baltimore Medical Center was founded in 1960 and is headquartered in Baltimore, MD. | Corporate Officer/Principal | - | - |
Hyperheal Hyperbarics, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2016 | - |
Karriereverlauf von Ziad Mirza
Ehemalige bekannte Positionen von Ziad Mirza
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INNOVUS PHARMACEUTICALS INC | Direktor/Vorstandsmitglied | 01.01.2012 | 14.02.2020 |
Vorsitzender | 01.03.2010 | 01.01.2012 | |
Independent Dir/Board Member | 01.03.2010 | 14.02.2020 | |
FasTrack Pharmaceuticals, Inc.
![]() FasTrack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FasTrack Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutic drugs including drugs to treat liver cancer and autoimmune diseases. Their lead product, PrevOnco, is a H+/K+-ATPase inhibitor, which was granted Orphan Drug Status by the FDA in August 2008. PrevOnco is currently in Phase 3 development as a potential second line therapy for patients with liver cancer. They also have an innovative pipeline of novel products for the Over-the Counter markets including Apeaz and Regia, indicated for pain relief and bleeding of the gums, respectively. | Vorstandsvorsitzender | 01.03.2010 | 01.12.2010 |
Ausbildung von Ziad Mirza
University of Massachusetts | Masters Business Admin |
American University of Beirut | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Libanon | 2 |
Operativ
Director/Board Member | 1 |
Chairman | 1 |
Independent Dir/Board Member | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Innovus Pharmaceuticals, Inc.
![]() Innovus Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Innovus Pharmaceuticals, Inc. engages in the commercialization, licensing, and development of non-prescription medicine, and consumer care products for health and vitality, and respiratory diseases. Its products focuses in six main categories, including sexual health, pain management, general muscle health, respiratory, sleep, and diabetic care. The company was founded on January 15, 1959 and is headquartered in Englewood, CO. | Health Technology |
Baltimore Medical & Surgical Associates | |
Greater Baltimore Medical Center
![]() Greater Baltimore Medical Center Hospital/Nursing ManagementHealth Services Greater Baltimore Medical Center provides health care services. It is a nearly 310 bed hospital which also operates the Hospice of Baltimore, the Hospice of Howard County, the Gilchrist Center for Hospice Care, plus various clinics and medical offices. Greater Baltimore Medical Center was founded in 1960 and is headquartered in Baltimore, MD. | Health Services |
Hyperheal Hyperbarics, Inc. | |
FasTrack Pharmaceuticals, Inc.
![]() FasTrack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FasTrack Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutic drugs including drugs to treat liver cancer and autoimmune diseases. Their lead product, PrevOnco, is a H+/K+-ATPase inhibitor, which was granted Orphan Drug Status by the FDA in August 2008. PrevOnco is currently in Phase 3 development as a potential second line therapy for patients with liver cancer. They also have an innovative pipeline of novel products for the Over-the Counter markets including Apeaz and Regia, indicated for pain relief and bleeding of the gums, respectively. | Health Technology |
- Börse
- Insiders
- Ziad Mirza
- Erfahrung